ArticleProbiotics and antimicrobial proteins2026
Computational Prioritisation of Fish-Derived Antimicrobial Peptides by Integrated Multi-Layer Immunogenicity and Structural Analysis.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fish-derived antimicrobial peptides (AMPs) represent a promising but underexplored source of therapeutic candidates. However, their immunological safety for potential human application has not been systematically evaluated. Here, we applied a multi-stage computational approach to 154 fish AMPs retrieved from the Antimicrobial Peptide Database (APD6). Sequential safety filtering reduced the dataset to 23 AMP candidates, which were subsequently evaluated using a composite safety and immunogenicity risk score based on MHC class I binding, MHC class II binding, B-cell epitope exposure, and residual hemolytic risk. B-cell risk was conditioned on MHC class II activation to account for the role of CD4⁺ T-cell help in class-switched antibody responses. Eight AMPs were classified as Predicted Low Risk based on their relative composite safety and immunogenicity risk. Both this classification and the rank order of the three highest-ranked candidates remained stable across the tested sensitivity scenarios. The eight Predicted Low Risk candidates were further evaluated for conformational variability, secondary structure, structural rigidity, and membrane interaction. NRC-01 showed the lowest composite safety and immunogenicity risk score (0.213), indicating the lowest predicted risk among the evaluated candidates. NRC-18 achieved the highest final multi-criteria score (0.764), combining a relatively low composite safety and immunogenicity risk score (0.296), strong predicted membrane interaction (ΔG = -5.2 kcal/mol), high helical content (69.0%), and the highest dominant cluster population among the top three candidates (57.86%). Overall, the combined computational analyses identified a small group of fish-derived AMPs with favourable predicted safety, immunogenicity, and structural characteristics that warrant further experimental investigation.
Indexed as
Identifiers
42842187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.